Circio Updates Terms of NOK 50 Million Rights Issue to Fund circRNA and Cancer Vaccine Programs

An announcement from Targovax ASA ( (GB:0RIS) ) is now available.

Circio Holding ASA has updated the key terms of its previously announced rights issue, which aims to raise up to NOK 50 million in gross proceeds through the issuance of up to 50 million new shares at NOK 1.00 per share. Existing shareholders as of 12 January 2026 will receive listed subscription rights on the Oslo Stock Exchange, with each right entitling the holder to subscribe for one new share, and subscribers will also receive one warrant per new share that can later be exercised to buy additional shares at a discount to the market-based price. The capital raise, which is largely underwritten and presubscribed and remains subject to approval at an extraordinary general meeting and the publication of a prospectus cleared by the Norwegian regulator, is intended to strengthen Circio’s financial position as it continues to develop its circRNA platform and TG01 cancer vaccine program, potentially reinforcing its technology leadership and funding runway in a competitive gene and cell therapy landscape.

More about Targovax ASA

Circio Holding ASA is a biotechnology company developing circular RNA (circRNA) expression technology aimed at enhancing gene and cell therapies. Its proprietary circVec platform is designed to deliver significantly longer RNA half-life and higher protein expression than conventional mRNA-based viral and non-viral vectors, targeting applications across genetic medicine, cell therapy and chronic disease. Through its Stockholm-based subsidiary Circio AB, the company conducts R&D on this platform while also advancing its legacy TG01 immuno-oncology peptide vaccine for RAS-mutated cancers via external academic and industry collaborations in Norway and the United States.

Average Trading Volume: 5,202,105

Current Market Cap: NOK176.9M

See more data about 0RIS stock on TipRanks’ Stock Analysis page.